Skip to main content
BEIJING LEADMAN BIOCHEMISTRY CO.,LTD. logo

BEIJING LEADMAN BIOCHEMISTRY CO.,LTD. — Investor Relations & Filings

Ticker · 300289 ISIN · CNE100001C22 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,951 across all filing types
Latest filing 2026-03-06 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300289

About BEIJING LEADMAN BIOCHEMISTRY CO.,LTD.

https://www.leadmanbio.com

Beijing Leadman Biochemistry Co., Ltd. specializes in the research, development, manufacturing, and distribution of in-vitro diagnostic (IVD) solutions. The company’s core portfolio includes a wide range of clinical chemistry reagents, chemiluminescence immunoassay kits, and automated diagnostic instruments. These products support various medical testing areas, such as liver and kidney function, lipid profiles, and cardiac markers. By providing integrated systems that combine high-performance reagents with specialized hardware, the company serves hospitals, clinical laboratories, and medical institutions. Its operations focus on delivering precise and efficient diagnostic tools to enhance clinical decision-making and patient care.

Recent filings

Filing Released Lang Actions
第六届董事会第八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of Beijing Lidemann Biochemical Co., Ltd. It details the approval of various company governance and management system revisions. The content focuses on board decisions and governance-related policies rather than financial results or reports. The document is titled as a board meeting resolution announcement and includes voting results for each proposal. It does not contain financial statements, earnings data, or audit information. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board or senior management.
2026-03-06 Chinese
财务管理制度（2026年3月）
Regulatory Filings Classification · 95% confidence The document is titled '北京利德曼生化股份有限公司财务管理制度' which translates to 'Beijing Lideman Biochemical Co., Ltd. Financial Management System'. It is a detailed internal financial management policy document covering various aspects such as financial personnel management, budgeting, cash management, asset management, investment, financing, guarantees, income, cost control, related party transactions, and financial reporting. The content is a comprehensive internal financial management manual or system, not a financial report, earnings release, or regulatory filing. It does not contain financial statements, audit opinions, or earnings data. It is not an announcement or a brief summary but a full internal policy document. Therefore, it does not fit categories like Annual Report (10-K), Interim Report (IR), Earnings Release (ER), or Audit Report (AR). It is also not a governance report (CGR) or remuneration report (DEF 14A). The document is a detailed internal financial management system, which is best classified under Regulatory Filings (RNS) as it is a regulatory/compliance related internal policy document that does not fit other specific categories.
2026-03-06 Chinese
募集资金管理制度（2026年3月）
Capital/Financing Update Classification · 95% confidence The document is titled '募集资金管理制度' which translates to 'Fundraising Capital Management System' and is issued by Beijing Leadman Biochemical Co., Ltd. It details the management, storage, usage, supervision, and change procedures of funds raised by the company through securities issuance. The content includes regulatory references, internal control measures, approval processes, and reporting requirements related to the management of raised capital. There is no indication that this is a financial report like an Annual Report (10-K) or Interim Report (IR), nor is it an announcement of voting results, board changes, or earnings. It is a detailed policy document governing the management of capital raised by the company, which aligns with the definition of a Capital/Financing Update (CAP) as it relates to fundraising and capital structure management. The document length (8654 characters) and detailed procedural content confirm it is not a brief announcement or a certification. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2026-03-06 Chinese
外汇套期保值业务管理制度（2026年3月）
Governance Information Classification · 95% confidence The document is titled as a management system for foreign exchange hedging business of Beijing Lidman Biochemical Co., Ltd. It outlines internal policies, operational procedures, approval authorities, risk management, and information disclosure related to the company's foreign exchange hedging activities. There are no financial statements, earnings data, or audit opinions presented. The document is a detailed internal governance and operational guideline rather than a financial report or announcement. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Audit Report. It is not a regulatory filing or announcement of a report but a formal internal policy document. The closest fitting category is Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document is 3580 characters, which is relatively short but contains substantive policy content rather than a mere announcement. Therefore, the classification is CGR with high confidence.
2026-03-06 Chinese
重大信息内部报告制度（2026年3月）
Governance Information Classification · 95% confidence The document is titled '北京利德曼生化股份有限公司重大信息内部报告制度' which translates to 'Beijing Leadman Biochemical Co., Ltd. Major Information Internal Reporting System.' The content describes internal procedures and rules for reporting major information within the company, including definitions of major information, reporting obligations, procedures, and responsibilities. It references relevant laws and stock exchange rules but does not contain financial statements, earnings data, or any form of financial results. It is a governance-related document outlining internal control and reporting mechanisms for material information. It is not a report of financial results, audit, or any announcement of voting or capital changes. It is a detailed governance and compliance policy document. Therefore, the most appropriate classification is Governance Information (CGR). The document length (over 11,000 characters) and detailed procedural content confirm it is not a brief announcement or a certification, so it is not RNS or RPA.
2026-03-06 Chinese
内幕信息知情人登记管理制度（2026年3月）
Governance Information Classification · 95% confidence The document is titled '北京利德曼生化股份有限公司内幕信息知情人登记管理制度' which translates to 'Beijing Leadman Biochemical Co., Ltd. Insider Information Insider Registration Management System.' The content details the company's internal policies and procedures for managing insider information, including definitions of insider information, the scope of insiders, registration and filing of insider information, confidentiality obligations, and responsibilities. It references relevant Chinese securities laws and regulatory requirements. There is no financial data, earnings information, or report publication announcement. The document is a governance-related internal policy document focused on compliance and insider information management. Therefore, it fits best under Governance Information (CGR). The document length (6871 characters) and detailed procedural content support this classification with high confidence.
2026-03-06 Chinese

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.